First In MS: Fingolimod Nears Market For Relapsing MS In Children, Adolescents
Per initial data from Novartis's PARADIGMS study in adolescents and children, Gilenya is the first therapy shown to reduce MS relapses in younger patients in a controlled late-stage clinical study, and Novartis says it will prepare marketing submissions for the additional indication after fully analyzing the data.
You may also be interested in...
The German group's oral treatment is late coming to the market but a key opinion leader believes that it will change the way multiple sclerosis is treated.
Novartis sees itself engaging in only modest M&A activity to avoid over-paying for targets - and will rely on newly launched drugs and promising external targets to grow sales.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.